<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01898494</url>
  </required_header>
  <id_info>
    <org_study_id>E3311</org_study_id>
    <secondary_id>NCI-2013-00814</secondary_id>
    <secondary_id>ECOG-E3311</secondary_id>
    <secondary_id>E3311</secondary_id>
    <secondary_id>E3311</secondary_id>
    <secondary_id>U10CA180820</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT01898494</nct_id>
  </id_info>
  <brief_title>Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer</brief_title>
  <official_title>Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies how well transoral surgery followed by low-dose or&#xD;
      standard-dose radiation therapy works in treating patients with human papilloma virus (HPV)&#xD;
      positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to&#xD;
      kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation&#xD;
      therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet&#xD;
      known how much extra treatment needs to be given after surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Accrual, risk distribution, and surgical quality will be used to determine the feasibility&#xD;
      of a prospective multi-institutional study of transoral surgery for HPV positive (+)&#xD;
      oropharynx cancer followed by risk-adjusted adjuvant therapy.&#xD;
&#xD;
      II. To assess the oncologic efficacy following transoral resection and adjuvant therapy in&#xD;
      patients determined to be at &quot;intermediate risk&quot; after surgical excision, the 2-year&#xD;
      progression free survival (PFS) rate will be examined.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the patient distribution with various histologic risk features. II. To assess&#xD;
      and compare early and late toxicities associated with transoral surgery (TOS) and the&#xD;
      different doses of adjuvant postoperative radiotherapy (PORT).&#xD;
&#xD;
      III. To evaluate swallowing function before and after TOS and risk-adjusted adjuvant therapy.&#xD;
&#xD;
      IV. To evaluate quality of life (QOL), swallowing perception and performance, voice outcomes,&#xD;
      and head and neck symptoms.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To correlate tumor TP53 mutation and other associated mutation profile with pathologic&#xD;
      findings, with PFS and other outcome parameters in patients with resectable HPV-associated&#xD;
      oropharyngeal squamous cell carcinoma (OPSCC) after the above treatments.&#xD;
&#xD;
      II. To evaluate radiation resistance markers, including excision repair cross complementing 1&#xD;
      (ERCC1) single nucleotide polymorphism and protein expression, and correlate them with&#xD;
      treatment efficacy.&#xD;
&#xD;
      III. To investigate the usefulness of biomarkers in predicting progression-free survival and&#xD;
      biomarkers, including tumor ERCC1, epidermal growth factor receptor (EGFR), plasma&#xD;
      cytokine/chemokines, cellular immunity to HPV, and oral HPV deoxyribonucleic acid (DNA).&#xD;
&#xD;
      OUTLINE: Patients are classified by risk status (low risk, intermediate risk, or high risk)&#xD;
      and assigned to the appropriate treatment group. Patients classified as intermediate risk are&#xD;
      randomized to 1 or 2 treatment arms.&#xD;
&#xD;
      ARM A (low risk): Patients undergo transoral surgical resection of the oropharyngeal tumor.&#xD;
&#xD;
      ARM B (intermediate risk): Patients undergo transoral surgical resection of the oropharyngeal&#xD;
      tumor. Patients then undergo low-dose intensity modulated radiation therapy (IMRT) once daily&#xD;
      (QD) five days a week for 5 weeks.&#xD;
&#xD;
      ARM C (intermediate risk): Patients undergo transoral surgical resection of the oropharyngeal&#xD;
      tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.&#xD;
&#xD;
      ARM D (high risk): Patients undergo transoral surgical resection of the oropharyngeal tumor.&#xD;
      Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also&#xD;
      receive cisplatin intravenously (IV) over 60 minutes or carboplatin IV over 30 minutes on&#xD;
      days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years and&#xD;
      then every 6 months for 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Actual">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the proportion of patients alive and progression-free at 24 months. Kaplan-Meier estimates will be calculated. 90% exact binomial confidence intervals will be computed for each arm. The 2-year failure proportions that include second primary cancers from the head and neck region as event will also be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accrual rate</measure>
    <time_frame>Up to 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Risk distribution</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>A 90% binomial confidence interval will be estimated for the percentage of patients in each risk group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3-4 bleeding events during surgery and positive margins after surgery, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The percentage will be deemed too high if 13 or more patients reported with grade 3-4 bleeding in the operating room or with positive margins, which corresponds to an empirical rate of 22%. A 90% binomial confidence interval will be estimated for these events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events evaluated by the CTCAE version 4.0</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The difference between arms will be evaluated using Fisher's exact test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time from registration onto the study until death from any cause, assessed up to 3 years</time_frame>
    <description>Kaplan-Meier estimates will be calculated, along with their corresponding 95% confidence intervals. The median, 1-year, and 2-year survival rates will be estimated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swallowing function before and after treatment, evaluated using the modified barium swallow (MBS) ratings, performance status scale for head and neck cancer (PSS-HN) normalcy of diet scale, and the MD Anderson Dysphagia Inventory (MDADI)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Descriptive statistics will be provided (by arm) for swallowing function, evaluated using the MBS ratings, PSS-HN normalcy of diet scale, and the validated survey MDADI instrument. Longitudinal analysis will be performed, by arm, on each of these measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Voice before and after treatment, evaluated using the Voice Handicap Index-10</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Longitudinal analysis will be performed, by arm, on each of these measures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported quality of life (QOL) as measured by Functional Assessment of Cancer Therapy-Head and Neck</measure>
    <time_frame>Baseline up to 6 months post radiation therapy</time_frame>
    <description>Patient QOL will be grouped as &quot;improved&quot; (change &gt;= 7 points, 6 months post-radiation therapy vs. baseline), &quot;worsened&quot; (change =&lt; -7 points) and &quot;stable&quot; (-6 =&lt; change =&lt; 6).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">511</enrollment>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>Stage III Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVA Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IVB Squamous Cell Carcinoma of the Oropharynx</condition>
  <arm_group>
    <arm_group_label>Arm A (TOS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo transoral surgical resection of the oropharyngeal tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (TOS, low-dose IMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo low-dose IMRT QD five days a week for 5 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (TOS, standard-dose IMRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (TOS, standard-dose IMRT, chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo transoral surgical resection of the oropharyngeal tumor. Patients then undergo standard-dose IMRT QD five days a week for 6-7 weeks. Patients also receive cisplatin IV over 60 minutes or carboplatin IV over 30 minutes on days 1, 8, 15, 22, 29, 36, and 43 during radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo transoral surgical resection</description>
    <arm_group_label>Arm A (TOS)</arm_group_label>
    <arm_group_label>Arm B (TOS, low-dose IMRT)</arm_group_label>
    <arm_group_label>Arm C (TOS, standard-dose IMRT)</arm_group_label>
    <arm_group_label>Arm D (TOS, standard-dose IMRT, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo low-dose IMRT</description>
    <arm_group_label>Arm B (TOS, low-dose IMRT)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm D (TOS, standard-dose IMRT, chemotherapy)</arm_group_label>
    <other_name>CACP</other_name>
    <other_name>CDDP</other_name>
    <other_name>CPDD</other_name>
    <other_name>DDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm D (TOS, standard-dose IMRT, chemotherapy)</arm_group_label>
    <other_name>Carboplat</other_name>
    <other_name>CBDCA</other_name>
    <other_name>JM-8</other_name>
    <other_name>Paraplat</other_name>
    <other_name>Paraplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
    <description>Undergo standard-dose IMRT</description>
    <arm_group_label>Arm C (TOS, standard-dose IMRT)</arm_group_label>
    <arm_group_label>Arm D (TOS, standard-dose IMRT, chemotherapy)</arm_group_label>
    <other_name>IMRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm A (TOS)</arm_group_label>
    <arm_group_label>Arm B (TOS, low-dose IMRT)</arm_group_label>
    <arm_group_label>Arm C (TOS, standard-dose IMRT)</arm_group_label>
    <arm_group_label>Arm D (TOS, standard-dose IMRT, chemotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm A (TOS)</arm_group_label>
    <arm_group_label>Arm B (TOS, low-dose IMRT)</arm_group_label>
    <arm_group_label>Arm C (TOS, standard-dose IMRT)</arm_group_label>
    <arm_group_label>Arm D (TOS, standard-dose IMRT, chemotherapy)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  REGISTRATION TO SURGERY (ARM S)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1&#xD;
&#xD;
          -  Patients must have newly diagnosed, histologically or cytologically confirmed squamous&#xD;
             cell carcinoma or undifferentiated carcinoma of the oropharynx; patients must have&#xD;
             been determined to have resectable oropharyngeal disease; patients with primary tumor&#xD;
             or nodal metastasis fixed to the carotid artery, skull base or cervical spine are not&#xD;
             eligible&#xD;
&#xD;
          -  Patients must have American Joint Committee on Cancer (AJCC) TNM tumor stage III, IV&#xD;
             a, or IV b (with no evidence of distant metastases) as determined by imaging studies&#xD;
             (performed &lt; 4 weeks prior to pre-registration) and complete head and neck exam; the&#xD;
             following imaging is required: computed tomography (CT) scan with IV contrast or&#xD;
             magnetic resonance imaging (MRI)&#xD;
&#xD;
          -  Patients must have biopsy-proven cyclin-dependent kinase inhibitor 2A (p16)+&#xD;
             oropharynx cancer; the histologic evidence of invasive squamous cell carcinoma may&#xD;
             have been obtained from the primary tumor or metastatic lymph node; it is required&#xD;
             that patients have nodal stage N1-N2b confirmed by clinical or radiographic methods&#xD;
             (clinically N0 patients are not eligible)&#xD;
&#xD;
          -  Carcinoma of the oropharynx associated with HPV as determined by p16 protein&#xD;
             expression using immunohistochemistry (IHC) performed by a Clinical Laboratory&#xD;
             Improvement Amendments (CLIA) approved laboratory; using p16 antibody obtained from&#xD;
             Roche mtm laboratories AG (CINtec, clone E6H4) is recommended&#xD;
&#xD;
          -  No prior radiation above the clavicles&#xD;
&#xD;
          -  Patients with a history of a curatively treated malignancy must be disease-free for at&#xD;
             least two years except for carcinoma in situ of cervix and/or non-melanomatous skin&#xD;
             cancer&#xD;
&#xD;
          -  Patients with the following within the last 6 months prior to pre-registration must be&#xD;
             evaluated by a cardiologist and/or neurologist prior to entry into the study&#xD;
&#xD;
          -  Patients must not have evidence of extensive or &quot;matted/fixed&quot; pathologic adenopathy&#xD;
             on preoperative imaging&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,500/mm^3&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Total bilirubin =&lt; the upper limit of normal (ULN)&#xD;
&#xD;
          -  Calculated creatinine clearance must be &gt; 60 ml/min using the Cockcroft-Gault formula&#xD;
&#xD;
          -  Women must not be pregnant or breast-feeding due to the teratogenicity of&#xD;
             chemotherapy; all females of childbearing potential must have a blood test or urine&#xD;
             study within 2 weeks prior to registration to rule out pregnancy; a female of&#xD;
             childbearing potential is any woman, regardless of sexual orientation or whether they&#xD;
             have undergone tubal ligation, who meets the following criteria: has not undergone a&#xD;
             hysterectomy or bilateral oophorectomy; or has not been naturally postmenopausal for&#xD;
             at least 24 consecutive months (i.e., has had menses at any time in the preceding 24&#xD;
             consecutive months)&#xD;
&#xD;
          -  Patient must not have an intercurrent illness likely to interfere with protocol&#xD;
             therapy or prevent surgical resection&#xD;
&#xD;
          -  Patients must not have uncontrolled diabetes, uncontrolled infection despite&#xD;
             antibiotics or uncontrolled hypertension within 30 days prior to pre-registration&#xD;
&#xD;
          -  REGISTRATION/RANDOMIZATION TO STEP 2 - ARMS A, B, C AND D AND REGISTRATION TO STEP 3&#xD;
&#xD;
          -  Histopathologic assessment of surgical pathology must include examination for&#xD;
             perineural invasion (PNI) and lymphovascular invasion (LVI) and reported as absent or&#xD;
             present; the absence or presence of extracapsular extension (ECE) requires gross and&#xD;
             microscopic assessment and is defined to be:&#xD;
&#xD;
               -  Absent (negative or nodal metastasis with smooth/rounded leading edge confined to&#xD;
                  thickened capsule/pseudocapsule),&#xD;
&#xD;
               -  Present - minimal (tumor extends =&lt; 1 mm beyond the lymph node capsule), or&#xD;
&#xD;
               -  Present - extensive (gross, tumor extends &gt; 1 mm beyond the lymph node capsule&#xD;
                  (includes soft tissue metastasis)&#xD;
&#xD;
          -  Patients must have ECOG performance status 0 or 1&#xD;
&#xD;
          -  Patient must be registered/randomized within 5-7 weeks following surgery&#xD;
&#xD;
          -  Women of childbearing potential and sexually active males are strongly advised to use&#xD;
             an accepted and effective method of contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Ferris</last_name>
    <role>Principal Investigator</role>
    <affiliation>ECOG-ACRIN Cancer Research Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Oakland-Broadway</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center-Mount Zion</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers-Boulder</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose-Saint Francis Healthcare</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers-Penrose</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Adventist Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center at Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa/Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Springfield</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Methodist Hospital</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center - Moses Campus</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467-2490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve University</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PinnacleHealth Cancer Center-Community Campus</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania/Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center-Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Cancer Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Cancer Institute at Sentara CarePlex Hospital</name>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <zip>23666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Hospitals</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Virginia Beach General Hospital</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zablocki Veterans Administration Medical Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2013</study_first_posted>
  <last_update_submitted>October 23, 2020</last_update_submitted>
  <last_update_submitted_qc>October 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Papilloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

